Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05335148 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety of Colchicine
A Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT05335148 is a Phase 1 study that is active but no longer recruiting, run by Rutgers, The State University of New Jersey. The registered enrollment target is 30 participants.
The verdict
NCT05335148, a Phase 1 study, is active but no longer recruiting, sponsored by Rutgers, The State University of New Jersey.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Currently, there are no approved medications for the prevention and treatment of radiation-induced dermatitis, or skin discoloration/burning due to radiation therapy, because there is little evidence to guide treatment. The purpose of the research is to better understand the factors associated with radiation-induced dermatitis and to explore the efficacy of low-dose colchicine in reducing the proportion of patients with radiation-induced dermatitis who undergo radiation treatment for head and neck cancer. If you take part in the research, you will be asked to take 0.6 mg once a day by mouth. The participants time in the study will take less than a minute a day to take the pill and 20 minutes to complete survey questions during follow-up visits.
Interventions
- DRUG oral colchicine(0.6 mg) once a day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-05-10 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05335148
The ClinicalTrials.gov registry entry for NCT05335148 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which oral colchicine(0.6 mg) once a day is the first listed.
NCT05335148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05335148 about?
NCT05335148 is a clinical study titled "Study to Evaluate the Safety of Colchicine". Currently, there are no approved medications for the prevention and treatment of radiation-induced dermatitis, or skin discoloration/burning due to radiation therapy, because there is little evidence to guide treatment. The purpose of the research is to better understand the factors associated with...
What is the current status of trial NCT05335148?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-05-10. Estimated completion is 2027-06-01.
What interventions are being tested in trial NCT05335148?
The interventions under investigation include: oral colchicine(0.6 mg) once a day (DRUG).
Who is sponsoring clinical trial NCT05335148?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.